Emergent (EBS.US) stock rose more than 40% before the market opened, as its smallpox vaccine was approved by the FDA for use in preventing monkeypox infection.
AInvestFriday, Aug 30, 2024 8:10 am ET
1min read
EBS --

Emergent BioSolutions (EBS.US) shares jumped more than 40% before the market opened on Friday after the FDA approved an expanded use of the company's ACAM2000 smallpox vaccine to allow its use in people at high risk for monkeypox infection.

Earlier this month, the World Health Organization (WHO) declared the current outbreak of monkeypox in Africa a "public health emergency of international concern."

Emergent's ACAM2000 is a single-dose, skin-applied live vaccine that was first approved by the FDA in 2007 for use in people at high risk for smallpox infection.

The latest approval was based on previously available human safety data and data from a controlled animal study in which the vaccine was shown to be effective in preventing monkeypox infection. Emergent had previously applied to WHO to have the ACAM2000 vaccine added to its emergency use authorization.

Emergent last week committed to donating 50,000 doses of ACAM2000 to countries affected by the monkeypox outbreak, including the Democratic Republic of Congo and Burundi, Kenya, Rwanda and Uganda.

Its competitor Bavarian Nordic's Jynneos vaccine is also approved in the U.S. for use against smallpox and monkeypox.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.